• Lyell Immunopharma will present updated ronde-cel lymphoma trial results at the American Society of Hematology meeting, December 12-15, 2026.
• Previously disclosed results showed high complete response rates and durable remissions in second-line and later-line relapsed or refractory large B-cell lymphoma.
• No severe cytokine release syndrome occurred in either cohort; severe neurotoxicity was uncommon, supporting potential outpatient administration.
• The pivotal PiNACLE trial is intended to support an initial application for regular marketing approval.
• A separate randomized Phase 3 trial compares ronde-cel with approved CD19-directed CAR T-cell therapies in second-line treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040901PRIMZONEFULLFEED9869904) on November 04, 2026, and is solely responsible for the information contained therein.